LOKMAN VARISLI1,2, VEYSEL TOLAN1, JIYAN H. CEN3, SPIROS VLAHOPOULOS4, OSMAN CEN5,6,*
Oncology Research, Vol.30, No.3, pp. 137-155, 2022, DOI:10.32604/or.2022.026074
Abstract Prostate cancer is one of the most often diagnosed malignancies in males and its prevalence is rising in both developed and developing countries. Androgen deprivation therapy has been used as a standard treatment approach for advanced prostate cancer for more than 80 years. The primary aim of androgen deprivation therapy is to decrease circulatory androgen and block androgen signaling. Although a partly remediation is accomplished at the beginning of treatment, some cell populations become refractory to androgen deprivation therapy and continue to metastasize. Recent evidences suggest that androgen deprivation therapy may cause cadherin switching, from E-cadherin to N-cadherin, which is… More >
Login
Register
